disability congenital anomaly requires intervention to prevent permanent impairment or damage A 44-year-old woman with type 1 diabetes mellitus developed factitious hypoglycaemia after secretly administering insulin, and insulin assays displayed cross-reactivity between insulin glargine and insulin lispro. The...
patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * requires intervention to prevent permanent impairment or damage A 20-year-old woman developed generalised insulin oedema after intensification of her insulin glargine [Lantus] and insulin lispro therapy....
in lispro overdose. Insulin glargine/insulin lispro overdose.Insulin glargine/insulin lispro overdose.The article cites a case report on the development of hypoglycaemia due to overdosage of insulin.EBSCO_AspReactions Weekly
Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro in... Background Glargine is a long-acting insulin analogue potentially more suitable than NPH insulin in intensive treatment of Type1 diabetes ...
diabetes: IMAGINE 1 A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial...
Aims and objective: To compare the efficacy and the incidence of hypoglycemia with addition of Insulin Glargine vs. NPH insulin in Type 2 Diabetes mellitus patients poorly controlled on OHA. Result and observation: Prior to initiating Insulin therapy mean value of HbA1c in group 1 and group 2 ...
(2008) Once-Daily Basal Insulin Glargine versus Thrice-Daily Prandial Insulin Lispro in People with Type 2 Diabetes on Oral Hypoglycaemic Agents (APOLLO), an Open Randomised Controlled Trial. The Lancet, 371, 1073-1084. http://dx.doi.org/10.1016/S0140-6736(08)60485-7 [32] Janka, H.U.,...
Lantus, INN insulin glargine European (地特胰岛素应用,酒店欧洲人).pdf,19 April 2012 EMA/CHMP/158966/2012 Committee for Medicinal Products for Human Use (CHMP) Assessment report Lantus insulin glargine Procedure No.: EMEA/H/C/000284/II/0075 Note Variat
A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 di... The primary objective was to demonstrate that basal insulin peglispro (BIL) was non‐inferior compared with insulin glargine (GL) for haemo...
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): A ... Blonde,Lawrence,Jendle,... - 《Lancet》 被引量: 67发表: 2015年 Efficacy and safety of once-weekly dulaglutide vs. Insulin glargine in...